FindTrial
Sign In

Luveltamab tazevibulin

DRUG3 trials

Sponsors

Sutro Biopharma, Inc.

Conditions

Acute Myeloid Leukemia (AML)Epithelial Ovarian CancerFallopian Tube CancerLung CancerLung Cancer MetastaticLung Cancer Non-Small Cell Stage IIIBLung Cancer Non-small Cell Stage IVLung Cancer, Non-small Cell

Phase 1

Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML
TerminatedNCT06679582
Sutro Biopharma, Inc.Acute Myeloid Leukemia (AML)
Start: 2024-12-04End: 2025-06-01Updated: 2025-08-24

Phase 2

REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
TerminatedNCT05870748
Sutro Biopharma, Inc.Epithelial Ovarian Cancer, Fallopian Tube Cancer, Ovarian Cancer +2
Start: 2023-07-12End: 2025-08-26Updated: 2025-09-23
Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer
WithdrawnNCT06555263
Sutro Biopharma, Inc.Lung Cancer, Lung Cancer Metastatic, Lung Cancer, Non-small Cell +3
Start: 2024-08-21End: 2025-05-01Updated: 2025-08-22

Related Papers

Data from The Anti-FRα Antibody–Drug Conjugate Luveltamab Tazevibulin Demonstrates Efficacy in Non–Small Cell Lung Cancer Preclinical Models and Induces Immunogenic Cell Death
2025-09-02
A phase 1/2, open-label study evaluating the efficacy, safety, and pharmacokinetics of luveltamab tazevibulin in infants and children &lt; 12 years of age with <i>CBFA2T3::GLIS2</i> acute myeloid leukemia.
Journal of Clinical Oncology2025-05-28
Long-term survival after luveltamab tazevibulin, a novel folate receptor-α (FRα) targeting antibody drug conjugate (ADC) in children with CBFA2T3::GLIS2 acute myeloid leukemia (AML).
Journal of Clinical Oncology2025-05-28
The Anti-FRα Antibody–Drug Conjugate Luveltamab Tazevibulin Demonstrates Efficacy in Non–Small Cell Lung Cancer Preclinical Models and Induces Immunogenic Cell Death
Molecular Cancer Therapeutics2025-04-281 citations
Abstract 3299: Anti-FRα antibody-drug conjugate luveltamab tazevibulin for the treatment of FRα-expressing non-small cell lung cancer
Cancer Research2025-04-21
Efficacy and safety of luveltamab tazevibulin vs investigator’s choice of chemotherapy in patients with recurrent platinum-resistant ovarian cancer (PROC) expressing folate receptor alpha (FRα): The REFRaME-01 (GOG-3086, ENGOT-79ov, and APGOT-OV9) phase 2/3 study.
Journal of Clinical Oncology2024-06-013 citations